US · HOWL
Werewolf Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Watertown, MA 02138
- Website
- werewolftx.com
Price · as of 2024-12-31
$0.72
Market cap 29.13M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $25.29 | +3,397.93% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $127.79 | +17,575.52% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $5.10 | ||||
| 2022 | $2.21 | ||||
| 2023 | $6.51 | $28.55 | $1.61 | $0.00 | $0.00 |
| 2024 | $1.23 | $25.29 | $0.00 | $0.00 | $127.79 |
AI valuation
Our deep-learning model estimates Werewolf Therapeutics, Inc.'s (HOWL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $25.29
- Current price
- $0.72
- AI upside
- +3,397.93%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
$127.79
+17,575.52% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HOWL | Werewolf Therapeutics, In… | $0.72 | 29.13M | +3,398% | — | — | +17,576% | -0.76 | 0.73 | 28.28 | 0.32 | -1.37 | 0.73 | 3.77% | -3904.19% | -3740.85% | -76.33% | -517.61% | -46.74% | 0.51 | -15.81 | 7.45 | 7.31 | 1.15 | 5524.00% | -9055.00% | 6908.00% | -105.90% | -3.70 | -396.98% | 0.00% | 0.00% | 0.00% | 0.28 | 0.37 | -10.93 | -4.95 |
| ACET | Adicet Bio, Inc. | $7.25 | 69.44M | — | — | — | — | -0.60 | 0.37 | — | 0.81 | — | 0.37 | 0.00% | — | — | -65.65% | -433.12% | -54.79% | 0.09 | -31903.75 | 9.29 | 9.09 | 0.35 | -5982.00% | — | -477.00% | -133.68% | -4.76 | -317.32% | 0.00% | 0.00% | 0.00% | 0.70 | 0.95 | — | -2.95 |
| CUE | Cue Biopharma, Inc. | $0.28 | 22.08M | +11,310% | +57% | — | — | -1.52 | 3.54 | 6.67 | -1.26 | — | 3.54 | 100.00% | -446.86% | -437.97% | -149.03% | -1327.36% | -86.80% | 0.51 | -52.14 | 1.84 | 1.78 | 0.36 | -3514.00% | 6916.00% | -892.00% | -58.74% | -2.65 | -1164.08% | 0.00% | 0.00% | 0.00% | -1.14 | -1.30 | 5.11 | -15.88 |
| INMB | INmune Bio, Inc. | $1.29 | 34.29M | +2,143% | +149% | — | +12,808% | -3.80 | 4.98 | 11425.06 | -3.31 | -14.43 | 10.26 | 100.00% | -304535.71% | -300585.71% | -119.83% | -351.09% | -87.16% | 0.01 | — | 3.14 | 3.09 | 0.49 | 2635.00% | -9097.00% | 17847.00% | -20.86% | -4.62 | -274.72% | 0.00% | 0.00% | 0.00% | -3.27 | -4.18 | 9958.06 | 4.00 |
| IOBT | IO Biotech, Inc. | $0.35 | 25.11M | — | — | — | — | -0.62 | 1.26 | — | -0.01 | — | 1.26 | 0.00% | — | — | -106.00% | 1021.32% | -87.44% | 0.04 | — | 3.33 | 3.14 | 0.62 | -2677.00% | — | 1434.00% | -138.96% | -4.23 | 884.12% | 0.00% | 0.00% | 0.00% | -0.01 | -0.01 | — | -9.54 |
| LITS | Lite Strategy, Inc. | $1.13 | 41.55M | +12,712% | — | — | — | -1.77 | 1.66 | — | -0.60 | — | 1.66 | 0.00% | — | — | -63.84% | 545.04% | -53.45% | 0.00 | — | 13.50 | 13.30 | 1.05 | -18951.00% | -10000.00% | -5871.00% | -73.96% | -15.39 | 650.87% | 0.00% | 0.00% | 50.76% | -0.58 | -0.49 | — | -20.49 |
| NRXP | NRx Pharmaceuticals, Inc. | $1.86 | 32.15M | — | — | — | — | -0.91 | -0.98 | — | -1.16 | — | -0.98 | 0.00% | — | — | 143.76% | 156.03% | -458.25% | -0.28 | -18.26 | 0.15 | 0.07 | -0.21 | -3995.00% | — | -5089.00% | -46.61% | -0.49 | 84.23% | 0.00% | 0.00% | 0.00% | -1.42 | -2.63 | — | -130.11 |
| OTLK | Outlook Therapeutics, Inc… | $0.42 | 17.31M | — | +90,898,778% | — | — | 0.00 | 0.00 | 50.46 | 123242.30 | — | 0.00 | 46.49% | -4744.25% | -4416.22% | 387.88% | 0.00% | -671.81% | -0.01 | -236.86 | 0.38 | 0.18 | 123243.42 | -5591.00% | — | 7534010988.00% | -72659652.79% | -1.13 | 259.00% | 0.00% | 0.00% | 10984444.51% | 116837.47 | 0.15 | -5543064.49 | -47.47 |
| SPRB | Spruce Biosciences, Inc. | $54.94 | 31.88M | +1,366% | +1,346% | — | +7,284% | -20.08 | 36.96 | 216.90 | -19.54 | -498.08 | 36.96 | 100.00% | -1143.37% | -1079.94% | -100.70% | 501.62% | -71.12% | 0.10 | -182.90 | 2.90 | 2.54 | 0.68 | 403.00% | -5132.00% | 6815.00% | -5.25% | -3.67 | 499.95% | 0.00% | 0.00% | 0.00% | -18.33 | -18.39 | 209.57 | 28.03 |
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
- CEO
- Daniel J. Hicklin
- Employees
- 46
- Beta
- 0.78
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.72) − 1 = — (DCF, example).